Loading...
Market
What will be the outcome of lawsuits involving Cassava Sciences by September 30, 2025?
2
Resolution / Starting Odds
Cassava Sciences wins the lawsuits • 25%
Cassava Sciences settles the lawsuits • 25%
Cassava Sciences loses the lawsuits • 25%
Lawsuits are dismissed • 25%
Publicly available legal filings and news reports
Story
Cassava Sciences and CEO Remi Barbier Charged by SEC Over Alzheimer's Drug Simufilam, Settle for $40 Million
Sep 26, 2024, 11:57 PM
Cassava Sciences and two former executives, including founder and CEO Remi Barbier and his wife, Lindsay Burns, have been charged by the U.S. Securities and Exchange Commission (SEC) for making misleading claims about the results of clinical trials for their Alzheimer's drug, simufilam. The company and the executives have agreed to pay over $40 million to settle the charges announced on Thursday. The SEC alleges that Cassava Sciences falsified Phase 2 trial data, with manipulated research results that showed no measurable cognitive improvement in patients' episodic memory. A Cassava-affiliated university scientist, Dr. Wang from CUNY, was also charged for manipulating clinical trial results.
View original story
Similar markets
Favorable ruling for Cassava Sciences • 25%
Unfavorable ruling for Cassava Sciences • 25%
Settlement • 25%
Case dismissed • 25%
Stock price above $50 • 25%
Stock price between $20 and $50 • 25%
Stock price between $5 and $20 • 25%
Stock price below $5 • 25%
Above $200 million • 25%
Between $100 million and $200 million • 25%
Between $50 million and $100 million • 25%
Below $50 million • 25%
Outperforms • 33%
Performs similarly • 34%
Underperforms • 33%
Yes • 50%
No • 50%
Below $1 billion • 25%
$1 billion to $1.5 billion • 25%
$1.5 billion to $2 billion • 25%
Above $2 billion • 25%
Below $20 • 25%
$20 to $40 • 25%
$40 to $60 • 25%
Above $60 • 25%